Virtual Poster Session in Hematology - prIME Oncology
Virtual Poster
Virtual Poster

Virtual Poster Session in Hematology

Key Data Presented During the 2019 Hematology Annual Meeting in Orlando

View Activities

Not a member of My prIME? Join now for instant access.

The information in this activity is intended for healthcare professionals based outside of the United States. This activity may contain information on products outside the approved indications where you practice.

Stay updated on the latest data from the annual hematology meeting in Orlando. Expert speakers present new trial data in AML, MPN, ITP, DLBCL, and CML.

Interactive Presentation

Interactive Presentation

Downloadable Slides

Downloadable Slides

IME

IME

Release Date

Release Date

Dec 17, 2019

Expiration Date

Dec 17, 2020

AML

Andrew Wei, MD, PhD

Abstract #LBA-3: The QUAZAR AML-001 maintenance trial: Results of a phase III international, randomized, double-blind, placebo-controlled study of CC-486 (oral formulation of azacitidine) in patients with acute myeloid leukemia (AML) in first remission

Featured Expert: Andrew Wei, MD, PhD

Naval G. Daver, MD

Abstract #734: Encouraging clinical profile of IMGN632, a novel CD123-targeting antibody-drug conjugate, in patients with relapsed/refractory acute myeloid leukemia or blastic plasmacytoid dendritic cell neoplasm

Featured Expert: Naval G. Daver, MD

Jorge Cortes, MD

Abstract #382: Quality-adjusted Time Without Symptoms or Toxicity (Q-TWiST) analysis of quizartinib vs salvage chemotherapy in patients with relapsed/refractory (R/R) FLT3-ITD acute myeloid leukemia (AML)

Featured Expert: Jorge Cortes, MD

Uma Borate, MD

Abstract #570: Phase Ib study of the anti-TIM-3 antibody MBG453 in combination with decitabine in patients with high-risk myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML)

Featured Expert: Uma Borate, MD

Dirk Reinhardt, MD

Abstract #3835: Phase II study of midostaurin + chemotherapy in pediatric patients with untreated, newly diagnosed, FLT3-mutated acute myeloid leukemia (AML)

Featured Expert: Dirk Reinhardt, MD

MPN

Aaron Gerds, MD

Abstract #667: Results of PAC203: A randomized phase 2 dose-finding study and determination of the recommended dose of pacritinib

Featured Expert: Aaron Gerds, MD

Ruben Mesa, MD, FACP

Abstract #668: Fedratinib induces spleen responses and reduces symptom burden in patients with myeloproliferative neoplasm (MPN)-associated myelofibrosis (MF) and low platelet counts, who were either ruxolitinib-naïve or were previously treated with ruxolitinib

Featured Expert: Ruben Mesa, MD, FACP

Jacqueline Garcia, MD

Abstract #671: Results from a phase 2 study of navitoclax in combination with ruxolitinib in patients with primary or secondary myelofibrosis

Featured Expert: Jacqueline Garcia, MD

ITP

Adrian Newland, MD

Abstract #895: Phase 2 study of efgartigimod, a novel FcRn antagonist, in adult patients with primary immune thrombocytopenia

Featured Expert: Adrian Newland, MD

Ivy Altomare, MD

Abstract #896: Perioperative eltrombopag or intravenous immune globulin for patients with immune thrombocytopenia: A multicenter randomized trial

Featured Expert: Ivy Altomare, MD

CML

Andreas Hochhaus, MD

Abstract #495: Nilotinib vs nilotinib plus pegylated interferon α (Peg-IFN) induction and nilotinib or Peg-IFN maintenance therapy for newly diagnosed BCR-ABL1 positive chronic myeloid leukemia patients in chronic phase (TIGER Study): The addition of Peg-IFN is associated with higher rates of deep molecular Response

Featured Expert: Andreas Hochhaus, MD

Fausto Castagnetti, MD, PhD

Abstract #496: Dose optimization in elderly CML patients treated with bosutinib after intolerance or failure of first-line tyrosine kinase inhibitors

Featured Expert: Fausto Castagnetti, MD, PhD

Jorge Cortes, MD

Abstract #705: Patient-reported outcome results from the U.S. Life After Stopping TKIs (LAST) study in patients with chronic myeloid leukemia

Featured Expert: Jorge Cortes, MD

DLBCL

Jeremy Abramson, MD

Abstract #241: Pivotal safety and efficacy results from Transcend NHL 001, a multicenter phase 1 study of lisocabtagene maraleucel (liso-cel) in relapsed/refractory (R/R) large B cell lymphomas

Featured Expert: Jeremy Abramson, MD

Veronika Bachanova, MD

Abstract #242: Impact of tisagenlecleucel chimeric antigen receptor (CAR)-T cell therapy product attributes on clinical outcomes in adults with relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL)

Featured Expert: Veronika Bachanova, MD

Max S. Topp, MD

Abstract #243: Earlier steroid use with axicabtagene ciloleucel (Axi-Cel) in patients with relapsed/refractory large B cell lymphoma

Featured Expert: Max S. Topp, MD

N. Nora Bennani, MD

Abstract #763: Experience with axicabtagene ciloleucel (axi-cel) in patients with secondary CNS involvement: Results from the US Lymphoma CAR T Consortium

Featured Expert: N. Nora Bennani, MD

Samantha Jaglowski, MD, MPH

Abstract #766: Tisagenlecleucel chimeric antigen receptor (CAR) T-cell therapy for adults with diffuse large B-cell lymphoma (DLBCL): Real world experience from the Center for International Blood & Marrow Transplant Research (CIBMTR) Cellular Therapy (CT) Registry

Featured Expert: Samantha Jaglowski, MD, MPH

  • Jeremy Abramson, MDDana-Farber Cancer Institute
    Boston, Massachusetts, United States
  • Ivy Altomare, MDDuke University Medical Center
    Durham, North Carolina, United States
  • Veronika Bachanova, MDUniversity of Minnesota
    Minneapolis, Minnesota, United States
  • N. Nora Bennani, MDMayo Clinic
    Rochester, Minnesota, United States
  • Uma Borate, MDOregon Health and Science University
    Portland, Oregon, United States
  • Fausto Castagnetti, MD, PhDBologna University School of Medicine
    Bologna, Italy
  • Jorge Cortes, MDAugusta University
    Augusta, Georgia, United States
  • Naval G. Daver, MDThe University of Texas
    MD Anderson Cancer Center
    Houston, Texas, United States
  • Jacqueline Garcia, MDDana-Farber Cancer Institute
    Boston, Massachusetts, United States
  • Aaron Gerds, MDCleveland Clinic
    Cleveland, Ohio, United States
  • Andreas Hochhaus, MDUniversity Medical Center
    Jena, Germany
  • Samantha Jaglowski, MD, MPHThe James
    The Ohio State University Comprehensive Cancer Center
    Columbus, Ohio, United States
  • Ruben Mesa, MD, FACPUniversity of Texas Health Science Center
    San Antonio, Texas, United States
  • Adrian Newland, MDBarts Health NHS Trust
    The Royal London Hospital
    London, United Kingdom
  • Dirk Reinhardt, MDUniversity of Duisburg-Essen
    Essen, Germany
  • Max S. Topp, MDUniversity of Würzburg
    Würzburg, Germany
  • Andrew Wei, MD, PhDAlfred Hospital and Monash University
    Melbourne, Australia

This educational activity is designed to meet the needs of practicing hematologists, oncologists, oncology nurses, researchers, and other healthcare professionals involved and/or interested in the management of patients with hematologic malignancies and their complications.

Upon completion of this activity, participants will:

  • Have increased knowledge regarding
    • Ongoing clinical trials for the enrollment of patients with hematologic malignancies
  • Have greater competence related to
    • Evaluating the latest clinical evidence supporting novel and emerging therapeutic strategies in hematologic malignancies
    • Selecting appropriate biomarkers for predicting therapeutic response in hematologic malignancies to improve patient outcomes

This educational activity is supported by a grant from Novartis Oncology.

Independent Medical Education (IME)

This IME activity is organized by prIME, a Medscape Oncology Company. This activity provides content that is evidence-based, balanced, and free of commercial bias, with a primary objective to improve competence and performance of learners in order to improve patient care.

Provider

This activity is provided by prIME, a Medscape Oncology Company.

Disclosure Information

Disclosure of Relevant Financial Relationships

prIME, a Medscape Oncology Company assesses relevant financial relationships with its instructors, planners, managers, and other individuals who are in a position to control the content of activities. Any potential conflicts of interest that are identified are thoroughly vetted by prIME, a Medscape Oncology Company for fairness, balance, and scientific objectivity of data, as well as patient care recommendations. prIME, a Medscape Oncology Company is committed to providing its learners with high-quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial entity. The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interest related to the content of this activity:

Dr Abramson has disclosed the following relevant financial relationships:

  • Served as an advisor or consultant for: AbbVie; Allogene; Bayer; Celgene; EMD Serono; Genentech; Roche; Gilead; Janssen; Karyopharm; Kite Pharma; Merck; Morphosys; Novartis; Verastem
  • Received grants for clinical research from: Seattle Genetics

Dr Altomare has disclosed the following relevant financial relationships:

  • Served as an advisor or consultant for: Amgen; Dova; Incyte; Novartis; Pfizer; Rigel

Dr Bachanova has disclosed the following relevant financial relationships:

  • Served as an advisor or consultant for: Gamida Cell; Kite; Unum
  • Received grants for clinical research from: Incyte; Gamida Cell

Dr Bennani has disclosed the following relevant financial relationships:

  • Served as an advisor or consultant for: Adicet Bio; Kite Pharma/Gilead; Purdue Pharma; Seattle Genetics

Dr Borate has disclosed the following relevant financial relationships:

  • Served as an advisor or consultant for: Agios; Daiichi Sankyo; Novartis; Takeda
  • Received grants for clinical research from: Incyte; Jazz

Dr Castagnetti has disclosed the following relevant financial relationships:

  • Served as an advisor or consultant for: Bristol-Myers Squibb; Incyte; Novartis; Pfizer
  • Served as a speaker or a member of a speakers bureau for: Bristol-Myers Squibb; Incyte; Novartis; Pfizer

Dr Cortes has disclosed the following relevant financial relationships:

  • Served as an advisor or consultant for: Astellas; Bristol-Myers Squibb; Daiichi;  Novartis; Pfizer; Takeda
  • Received grants for clinical research from: Amphivena; Astellas; Bristol-Myers Squibb; Daiichi; Merus; Novartis; Pfizer; Sun Pharma; Takeda
  • Owns stock, stock options, or bonds from: Arog; Eorma

Dr Daver has disclosed the following relevant financial relationships:

  • Served as an advisor or consultant for: AbbVie; Agios; Astellas; Bristol-Myers Squibb; Celgene; Daiichi-Sankyo; Forty-Seven; Genentech; Immunogen; Incyte; Jazz; Novartis; Pfizer; Servier
  • Received grants for clinical research from: AbbVie; Astellas; Bristol-Myers Squibb; Daiichi-Sankyo; Forty-Seven; Genentech; Immunogen; Incyte; Kiromics; Novimmune Pfizer; Servier

Dr Garcia has disclosed the following relevant financial relationships:

  • Served as an advisor or consultant for: AbbVie
  • Received grants for clinical research from: AbbVie; Genentech; Lilly; Pfizer

Dr Gerds has disclosed the following relevant financial relationships:

  • Served as an advisor or consultant for: Celgene; CTI Biopharma; Pfizer
  • Received grants for clinical research from: Celgene; CTI Biopharma; Imago; Incyte; Roche; Sierra Oncology

Dr Hochhaus has disclosed the following relevant financial relationships:

  • Served as a speaker or a member of a speakers bureau for: Bristol-Myers Squibb
  • Received grants for clinical research from: Bristol-Myers Squibb; Incyte; Novartis; Pfizer

Dr Jaglowski has disclosed the following relevant financial relationships:

  • Served as an advisor or consultant for: CRISPR Therapeutics; Juno; Kite; Novartis;
  • Served as a speaker or a member of a speakers bureau for: Novartis
  • Received grants for clinical research from: Kite; Novartis; Unum Therapeutics

Dr Mesa has disclosed the following relevant financial relationships:

  • Served as an advisor or consultant for: La Jolla Pharmaceutical; Novartis; Samus
  • Received grants for clinical research from: Celgene; CTI; Incyte; Promedior

Dr Newland has disclosed the following relevant financial relationships:

  • Served as an advisor or consultant for: Amgen; Angle; Argenx; Novartis; Ono; Pfizer; Shionogi
  • Served as a speaker or a member of a speakers bureau for: Amgen; Argenx; Novartis
  • Received grants for clinical research from: Amgen; Novartis

Dr Reinhardt has disclosed the following relevant financial relationships:

  • Served as an advisor or consultant for: AbbVie; Bluebird; Bristol-Myers Squibb; Janssen
  • Served as a speaker or a member of a speakers bureau for: Bluebird Bio
  • Received grants for clinical research from: CLS-Behring; Roche

Dr Topp has disclosed the following relevant financial relationships:

  • Served as an advisor or consultant for: Gilead
  • Received grants for clinical research from: Gilead

Dr Wei has disclosed the following relevant financial relationships:

  • Served as an advisor or consultant for: AbbVie; Amgen; Celgene; Janssen; Macrogenics; Novartis; Pfizer; Roche; Servier
  • Served as a speaker or a member of a speakers bureau for: AbbVie; Novartis
  • Received grants for clinical research from: AbbVie; Celgene; Novartis; Servier
  • Other: Former employee entitled to royalty payments in relation to Venetoclax

The employees of prIME, a Medscape Oncology Company have disclosed no relevant financial relationships.

Content Reviewers

Hazel Dennison, DNP, RN, FNP, CPHQ, CNE
Associate Director, Accreditation and Compliance

Disclosure: Hazel Dennison, DNP, RN, FNP, CPHQ, CNE, has disclosed no relevant financial relationships.

Esther Nyarko, PharmD
Associate Director, Accreditation and Compliance

Disclosure: Esther Nyarko, PharmD, has disclosed no relevant financial relationships.

Disclosure Regarding Unlabeled Use

This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product discussed for discussions of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.